JP3510889B2 - 糖尿病及び前糖尿症状の診断のための方法 - Google Patents
糖尿病及び前糖尿症状の診断のための方法Info
- Publication number
- JP3510889B2 JP3510889B2 JP51744894A JP51744894A JP3510889B2 JP 3510889 B2 JP3510889 B2 JP 3510889B2 JP 51744894 A JP51744894 A JP 51744894A JP 51744894 A JP51744894 A JP 51744894A JP 3510889 B2 JP3510889 B2 JP 3510889B2
- Authority
- JP
- Japan
- Prior art keywords
- gad
- preparation
- serum
- iddm
- autoantibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 26
- 206010018429 Glucose tolerance impaired Diseases 0.000 title claims abstract description 10
- 238000003745 diagnosis Methods 0.000 title description 4
- 208000024891 symptom Diseases 0.000 title description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims abstract description 253
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims abstract description 243
- 210000002966 serum Anatomy 0.000 claims abstract description 92
- 238000002360 preparation method Methods 0.000 claims abstract description 76
- 239000000539 dimer Substances 0.000 claims abstract description 30
- 102000001708 Protein Isoforms Human genes 0.000 claims abstract description 13
- 108010029485 Protein Isoforms Proteins 0.000 claims abstract description 13
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 6
- 210000004556 brain Anatomy 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 239000000178 monomer Substances 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 208000001280 Prediabetic State Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 239000000833 heterodimer Substances 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims 3
- 239000000710 homodimer Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 35
- 102000036639 antigens Human genes 0.000 abstract description 33
- 108091007433 antigens Proteins 0.000 abstract description 33
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 98
- 238000001114 immunoprecipitation Methods 0.000 description 29
- 238000003556 assay Methods 0.000 description 23
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 22
- 230000009257 reactivity Effects 0.000 description 22
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 18
- 238000001556 precipitation Methods 0.000 description 16
- 238000000376 autoradiography Methods 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 101150014889 Gad1 gene Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 210000004153 islets of langerhan Anatomy 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 108091005979 iodinated proteins Proteins 0.000 description 4
- 210000001995 reticulocyte Anatomy 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 108020003519 protein disulfide isomerase Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 101000873546 Homo sapiens Glutamate decarboxylase 1 Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000014267 Thyroid peroxidases Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002621 immunoprecipitating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000013631 noncovalent dimer Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Rehabilitation Therapy (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPL716893 | 1993-02-09 | ||
| AU7168 | 1993-02-09 | ||
| PCT/AU1994/000056 WO1994018568A1 (en) | 1993-02-09 | 1994-02-09 | Methods for the diagnosis of diabetes and prediabetic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08506417A JPH08506417A (ja) | 1996-07-09 |
| JP3510889B2 true JP3510889B2 (ja) | 2004-03-29 |
Family
ID=3776693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51744894A Expired - Fee Related JP3510889B2 (ja) | 1993-02-09 | 1994-02-09 | 糖尿病及び前糖尿症状の診断のための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5770381A (enExample) |
| EP (1) | EP0686262B1 (enExample) |
| JP (1) | JP3510889B2 (enExample) |
| AT (1) | ATE229650T1 (enExample) |
| CA (1) | CA2155677A1 (enExample) |
| DE (1) | DE69431874D1 (enExample) |
| IL (1) | IL108587A (enExample) |
| NZ (1) | NZ261541A (enExample) |
| SG (1) | SG45161A1 (enExample) |
| TW (1) | TW305936B (enExample) |
| WO (1) | WO1994018568A1 (enExample) |
| ZA (1) | ZA94845B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821334A (en) * | 1996-01-26 | 1998-10-13 | Vanderbilt University | Insulin-dependent diabetes mellitus-specific chimeric polypeptides |
| FR2759701B1 (fr) * | 1997-02-19 | 1999-06-04 | Inst Nat Sante Rech Med | Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques |
| AU3958999A (en) * | 1999-06-01 | 2000-12-18 | Kyokuto Pharmaceutical Industrial Co., Ltd. | Method for assaying anti-gad antibody and kit |
| ES2684976T3 (es) | 2012-04-13 | 2018-10-05 | Diabetomics, Inc. | Biomarcadores maternos para diabetes gestacional |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682906B1 (en) * | 1990-09-21 | 2004-01-27 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase |
| DE69233507T2 (de) * | 1991-02-22 | 2009-09-10 | The Walter And Eliza Hall Institute Of Medical Research, Parkville | Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten |
| WO1992019972A1 (en) * | 1991-05-03 | 1992-11-12 | Novo Nordisk A/S | Islet cell autoantigen (gad) for the detection of preclinical diabetes |
-
1994
- 1994-02-08 TW TW083101065A patent/TW305936B/zh active
- 1994-02-08 ZA ZA94845A patent/ZA94845B/xx unknown
- 1994-02-08 IL IL108587A patent/IL108587A/en not_active IP Right Cessation
- 1994-02-09 WO PCT/AU1994/000056 patent/WO1994018568A1/en not_active Ceased
- 1994-02-09 US US08/495,584 patent/US5770381A/en not_active Expired - Fee Related
- 1994-02-09 EP EP94906796A patent/EP0686262B1/en not_active Expired - Lifetime
- 1994-02-09 CA CA002155677A patent/CA2155677A1/en not_active Abandoned
- 1994-02-09 JP JP51744894A patent/JP3510889B2/ja not_active Expired - Fee Related
- 1994-02-09 SG SG1996000807A patent/SG45161A1/en unknown
- 1994-02-09 AT AT94906796T patent/ATE229650T1/de not_active IP Right Cessation
- 1994-02-09 NZ NZ261541A patent/NZ261541A/en unknown
- 1994-02-09 DE DE69431874T patent/DE69431874D1/de not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| Ｄｉａｂｅｔｅｓ Ｖｏｌ．１：３８Ａ，ａｂｓｔｒｕｃｔ １４８，１９９２ |
Also Published As
| Publication number | Publication date |
|---|---|
| IL108587A (en) | 1998-01-04 |
| US5770381A (en) | 1998-06-23 |
| EP0686262A1 (en) | 1995-12-13 |
| TW305936B (enExample) | 1997-05-21 |
| NZ261541A (en) | 1996-09-25 |
| WO1994018568A1 (en) | 1994-08-18 |
| IL108587A0 (en) | 1994-05-30 |
| SG45161A1 (en) | 1998-01-16 |
| ZA94845B (en) | 1994-11-11 |
| EP0686262B1 (en) | 2002-12-11 |
| EP0686262A4 (en) | 1997-06-04 |
| ATE229650T1 (de) | 2002-12-15 |
| JPH08506417A (ja) | 1996-07-09 |
| DE69431874D1 (de) | 2003-01-23 |
| CA2155677A1 (en) | 1994-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK167825B1 (da) | Fremgangsmaade og reagenssystem til immunobestemmelse af glycoprotein-analyten hb alc. | |
| US9435797B2 (en) | Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin | |
| Arif et al. | Identification of 3 beta-hydroxysteroid dehydrogenase as a novel target of steroid cell autoantibodies: association of autoantibodies with endocrine autoimmune disease | |
| US7718386B1 (en) | Methods for the diagnosis of diabetes | |
| TW201339578A (zh) | 在低傳導率下具有增加之靈敏度的自體抗體測量 | |
| KR910700459A (ko) | 인슐린 의존성 진성당뇨병의 조기검진 및 치료를 위한 방법 및 조성물 | |
| IL116617A (en) | Monoclonal antibody 4g9, 2g6 or bh4, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts | |
| Betterle et al. | Demonstration and characterization of anti-human mitochondria autoantibodies in idiopathic hypoparathyroidism and in other conditions | |
| JP3510889B2 (ja) | 糖尿病及び前糖尿症状の診断のための方法 | |
| JP3425149B2 (ja) | 無症候性患者における糖尿病可能性評価方法 | |
| US5674692A (en) | Methods for diabetes susceptibility assessment in asymptomatic patients | |
| CN114152753A (zh) | 一种用于检测人Dsg3 IgG抗体的ELISA试剂盒及其应用 | |
| JP2000502793A (ja) | Ｅｌｉｓａ試験システム | |
| Timsit et al. | Islet cell antibody heterogeneity among type 1 (insulin-dependent) diabetic patients | |
| Nakachi et al. | Epitopes recognised by tissue transglutaminase antibodies in coeliac disease | |
| JP3989837B2 (ja) | 抗ラミニン−１抗体の測定法およびその応用 | |
| JP4283812B2 (ja) | 重症筋無力症の診断方法およびそのキット | |
| AU688304B2 (en) | Methods for the diagnosis of diabetes and prediabetic conditions | |
| US5407802A (en) | Method of accessing the risks of developing type I diabetes | |
| JP2915530B2 (ja) | ラミニン フラグメント | |
| US5312628A (en) | Isolation of a soluble 42 KD pancreatic islet cell autoantigen | |
| FI104219B (fi) | Diagnostinen menetelmä ja testaustarvikesarja multippeliskleroosin määrittämiseksi | |
| Gleeson et al. | Parietal cell autoantibodies | |
| WO1993013420A1 (en) | Method of assessing the risks of developing type i diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040105 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090109 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090109 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100109 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110109 Year of fee payment: 7 |
|
| LAPS | Cancellation because of no payment of annual fees |